期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 22, 期 1, 页码 -出版社
MDPI
DOI: 10.3390/ijms22010091
关键词
mitochondrial dynamics; fusion; fission; mitophagy; sarcopenia; FGF21; GDF15; mitokines; myokines
资金
- AFM-Telethon [22457]
- STARS Consolidator Grant STARS-CoG 2019 ProMeMix
Sarcopenia is a chronic disease characterized by the progressive loss of skeletal muscle mass, force, and function during aging. The decline in mitochondrial quality control pathways is a major mechanism driving aging sarcopenia, with mitochondrial dysfunction influencing whole-body homeostasis. This dysfunction releases specific myomitokines that impact healthy or unhealthy aging.
Sarcopenia is a chronic disease characterized by the progressive loss of skeletal muscle mass, force, and function during aging. It is an emerging public problem associated with poor quality of life, disability, frailty, and high mortality. A decline in mitochondria quality control pathways constitutes a major mechanism driving aging sarcopenia, causing abnormal organelle accumulation over a lifetime. The resulting mitochondrial dysfunction in sarcopenic muscles feedbacks systemically by releasing the myomitokines fibroblast growth factor 21 (FGF21) and growth and differentiation factor 15 (GDF15), influencing the whole-body homeostasis and dictating healthy or unhealthy aging. This review describes the principal pathways controlling mitochondrial quality, many of which are potential therapeutic targets against muscle aging, and the connection between mitochondrial dysfunction and the myomitokines FGF21 and GDF15 in the pathogenesis of aging sarcopenia.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据